After logging a 1.6% gain during regular trading hours today, Tilray Brands (TLRY 3.67%) is racing higher in after-hours trading. The company reported second-quarter fiscal 2026 financial results after the bell rang, and investors are riding high on the company's report.
As of 6:17 p.m., shares of the medical cannabis stock are up 6.9% from their closing price of $9.13 during today's regular market session.
Image source: Getty Images.
The company's record quarter has investors feeling good
Growing sales 3% year-over-year, Tilray reported $218 million in revenue for Q2 2026, a company record. Analysts had anticipated Tilray reporting $211.15 million on the top line.
NASDAQ: TLRY
Key Data Points
Investors are also celebrating the company's progress toward profitability. In Q2 2026, Tilray reported a diluted earnings per share (EPS) of negative $0.41 -- a slimmer loss than the diluted EPS of negative $0.99 that it incurred during the same period last year.
The company also reported improvements in its cash flow statement. In Q2 2026, Tilray reported a negative operating cash flow of $8.5 million compared to the negative $40.7 million in cash from operating activities that it reported in Q2 2024.
A strong quarter suggests a green light for Tilray stock
From its strong year-over-year revenue growth to a slimmer net loss to a smaller operating cash outflow, there are several signs indicating that Tilray performed well in Q2 2026. While the company is still unprofitable, its strong balance sheet, which features a net cash position of $27.4 million, provides some reassurance that the company's not suffering from poor financial health. For investors interested in growing their cannabis exposure, Tilray stock is definitely worth a closer look right now.
